These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 7978043

  • 1. Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor.
    Raney B, Ensign LG, Foreman J, Khan F, Newton W, Ortega J, Ragab A, Wharam M, Wiener E, Maurer H.
    Am J Pediatr Hematol Oncol; 1994 Nov; 16(4):286-95. PubMed ID: 7978043
    [Abstract] [Full Text] [Related]

  • 2. Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen.
    Schütte J, Kellner R, Seeber S.
    Cancer Chemother Pharmacol; 1993 Nov; 31 Suppl 2():S194-8. PubMed ID: 8453697
    [Abstract] [Full Text] [Related]

  • 3. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
    Hawkins DS, Felgenhauer J, Park J, Kreissman S, Thomson B, Douglas J, Rowley SD, Gooley T, Sanders JE, Pendergrass TW.
    Cancer; 2002 Sep 15; 95(6):1354-65. PubMed ID: 12216105
    [Abstract] [Full Text] [Related]

  • 4. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children.
    Loebstein R, Atanackovic G, Bishai R, Wolpin J, Khattak S, Hashemi G, Gobrial M, Baruchel S, Ito S, Koren G.
    J Clin Pharmacol; 1999 May 15; 39(5):454-61. PubMed ID: 10234592
    [Abstract] [Full Text] [Related]

  • 5. A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS) IV pilot study.
    Arndt C, Tefft M, Gehan E, Anderson J, Jenson M, Link M, Donaldson S, Breneman J, Wiener E, Webber B, Maurer H.
    J Pediatr Hematol Oncol; 1997 May 15; 19(2):124-9. PubMed ID: 9149741
    [Abstract] [Full Text] [Related]

  • 6. Long-term evaluation of Ifosfamide-related nephrotoxicity in children.
    Oberlin O, Fawaz O, Rey A, Niaudet P, Ridola V, Orbach D, Bergeron C, Defachelles AS, Gentet JC, Schmitt C, Rubie H, Munzer M, Plantaz D, Deville A, Minard V, Corradini N, Leverger G, de Vathaire F.
    J Clin Oncol; 2009 Nov 10; 27(32):5350-5. PubMed ID: 19826134
    [Abstract] [Full Text] [Related]

  • 7. Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group.
    Spunt SL, Smith LM, Ruymann FB, Qualman SJ, Donaldson SS, Rodeberg DA, Anderson JR, Crist WM, Link MP.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 1):6072-9. PubMed ID: 15447992
    [Abstract] [Full Text] [Related]

  • 8. The IVADo regimen--a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study of behalf of the European pediatric Soft tissue sarcoma Study Group.
    Bisogno G, Ferrari A, Bergeron C, Scagnellato A, Prete A, Alaggio R, Casanova M, D'Angelo P, Di Cataldo A, Carli M.
    Cancer; 2005 Apr 15; 103(8):1719-24. PubMed ID: 15754335
    [Abstract] [Full Text] [Related]

  • 9. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol.
    Casanova M, Ferrari A, Bisogno G, Merks JH, De Salvo GL, Meazza C, Tettoni K, Provenzi M, Mazzarino I, Carli M.
    Cancer; 2004 Oct 01; 101(7):1664-71. PubMed ID: 15378498
    [Abstract] [Full Text] [Related]

  • 10. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group.
    Skinner R, Cotterill SJ, Stevens MC.
    Br J Cancer; 2000 May 01; 82(10):1636-45. PubMed ID: 10817497
    [Abstract] [Full Text] [Related]

  • 11. High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity.
    Berrak SG, Pearson M, Berberoğlu S, Ilhan IE, Jaffe N.
    Pediatr Blood Cancer; 2005 Mar 01; 44(3):215-9. PubMed ID: 15503294
    [Abstract] [Full Text] [Related]

  • 12. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System.
    Stöhr W, Paulides M, Bielack S, Jürgens H, Treuner J, Rossi R, Langer T, Beck JD.
    Pediatr Blood Cancer; 2007 Apr 01; 48(4):447-52. PubMed ID: 16628552
    [Abstract] [Full Text] [Related]

  • 13. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
    Navid F, Santana VM, Billups CA, Merchant TE, Furman WL, Spunt SL, Cain AM, Rao BN, Hale GA, Pappo AS.
    Cancer; 2006 Apr 15; 106(8):1846-56. PubMed ID: 16541446
    [Abstract] [Full Text] [Related]

  • 14. Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study.
    Budd GT, Metch B, Weiss SA, Weick JK, Fabian C, Stephens RL, Balcerzak SP.
    Cancer Chemother Pharmacol; 1993 Apr 15; 31 Suppl 2():S213-6. PubMed ID: 8453701
    [Abstract] [Full Text] [Related]

  • 15. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
    Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, Alvegard TA, Picci P, Capanna R, Bernini G, Müller C, Tienghi A, Wiebe T, Comandone A, Böhling T, Del Prever AB, Brosjö O, Bacci G, Saeter G, Italian and Scandinavian Sarcoma Groups.
    J Clin Oncol; 2005 Dec 01; 23(34):8845-52. PubMed ID: 16246977
    [Abstract] [Full Text] [Related]

  • 16. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience.
    Van Winkle P, Angiolillo A, Krailo M, Cheung YK, Anderson B, Davenport V, Reaman G, Cairo MS.
    Pediatr Blood Cancer; 2005 Apr 01; 44(4):338-47. PubMed ID: 15503297
    [Abstract] [Full Text] [Related]

  • 17. Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response.
    Ruymann FB, Vietti T, Gehan E, Wiener E, Wharam M, Newton WA, Maurer H.
    J Pediatr Hematol Oncol; 1995 Nov 01; 17(4):331-7. PubMed ID: 7583389
    [Abstract] [Full Text] [Related]

  • 18. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults.
    Dantonello TM, Int-Veen C, Harms D, Leuschner I, Schmidt BF, Herbst M, Juergens H, Scheel-Walter HG, Bielack SS, Klingebiel T, Dickerhoff R, Kirsch S, Brecht I, Schmelzle R, Greulich M, Gadner H, Greiner J, Marky I, Treuner J, Koscielniak E.
    J Clin Oncol; 2009 Mar 20; 27(9):1446-55. PubMed ID: 19224858
    [Abstract] [Full Text] [Related]

  • 19. [High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients].
    Baranzelli MC, Pichon F, Gourmel B, N'Guyen M, Deligny N, Demaille MC.
    Bull Cancer; 1997 Feb 20; 84(2):141-6. PubMed ID: 9180836
    [Abstract] [Full Text] [Related]

  • 20. Ifosfamide combination regimens for soft-tissue sarcoma.
    Stuart-Harris R, Dalley D, Bell DR, Levi J, Simes RJ, Wiltshaw E.
    Cancer Chemother Pharmacol; 1993 Feb 20; 31 Suppl 2():S185-8. PubMed ID: 8453695
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.